NCCN Issues First Guidelines for Pediatric Rhabdomyosarcoma, the Most Common Childhood Sof

Treating cancer in a three-year-old is not the same as treating cancer in a 60-year-old. The biology differs. The drug tolerances differ. The definition of a successful outcome differs - for a child, the goal is not prolonged survival but complete cure with minimal effects on development, growth, and long-term health. Until now, clinicians treating pediatric soft tissue sarcomas lacked comprehensive, regularly updated national guidelines of the kind that have long existed for adult cancers.

The National Comprehensive Cancer Network (NCCN) addressed that gap in February 2026 with the publication of new NCCN Clinical Practice Guidelines for Pediatric Soft Tissue Sarcomas. It is the 7th NCCN Guidelines document focused specifically on pediatric cancer, expanding a library that now covers 91 topics in cancer care. The new guidelines focus primarily on rhabdomyosarcoma (RMS), the most common type of soft tissue sarcoma in people under 20.

What Makes RMS Different

Rhabdomyosarcoma arises from primitive mesenchymal cells - the precursors to skeletal muscle. It can develop almost anywhere in the body, which contributes to diagnostic difficulty. When it appears in the head, neck, or a limb, it typically presents as a lump that may or may not be painful. When it develops on an internal organ, it may cause breathing or urinary problems before becoming visible or palpable. About 350 new cases are diagnosed in the United States each year, representing approximately 5 percent of all childhood cancers.

The disease is not a single entity. RMS divides into distinct subtypes driven by different genetic changes. The most common types are embryonal RMS and alveolar RMS; alveolar RMS, associated with PAX/FOXO fusion genes, carries a worse prognosis. Those genetic distinctions drive treatment decisions.

"Most cancers that occur in children are fundamentally different from cancers occurring in adults," said Stephen Skapek, MD, of Duke Cancer Institute, chair of the NCCN Guidelines Panel for Pediatric Soft Tissue Sarcoma. "RMS can be divided into specific subtypes that are driven by different genetic changes that can influence outcomes. Those changes and other clinical and pathology features are all incorporated into the multi-faceted treatments."

Three Risk Groups, Different Goals

The NCCN guidelines organize treatment recommendations around three risk groups - low, intermediate, and high - based on tumor histology, extent of disease, and surgical resectability at diagnosis. Survival rates differ substantially across groups, and treatment intensity is calibrated accordingly.

For low-risk patients, where cure rates exceed 90 percent with current approaches, the guidelines aim to achieve cure while minimizing exposure to treatments that carry long-term consequences. Radiation therapy can affect bone growth, endocrine function, and cognitive development when used in children under five. For high-risk patients, where outcomes remain poor despite aggressive treatment, the guidelines reflect current evidence while strongly encouraging clinical trial participation.

Douglas Hawkins, MD, Panel Vice-Chair from Seattle Children's, described the treatment philosophy: "When treating someone so young, you are not looking to just prolong survival, the goal is a full cure with minimal side effects and zero recurrence."

Why Dedicated Pediatric Guidelines Matter

Adult cancer guidelines cannot simply be applied to children. Pediatric patients metabolize drugs differently, tolerate doses differently, and face different late-effect profiles. The organs most vulnerable to treatment-related damage in children - growing bones, developing nervous systems, immature endocrine glands - are not the same as in adults.

RMS is treated with a combination of chemotherapy, surgery, and radiation therapy. The specific drugs, doses, and sequence are tailored to the risk group and the patient's age and developmental stage. Achieving the right combination requires input from pediatric oncologists, surgeons, radiation oncologists, and supportive care specialists.

The guidelines are available for free download at NCCN.org. NCCN guidelines were downloaded more than 18.4 million times in 2025. Independent studies consistently find that guideline-concordant care is associated with better patient outcomes and lower total costs.